Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Crespo

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
Expert Opinion on Drug Safety|December 29, 2021
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated reviewJavier De Diego-Adeliño, José Manuel Crespo, Fernando Mora, et al.
AIDS (London, England)|May 21, 2005
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapineCesar Fisac, Emilio Fumero, Manuel Crespo, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2018
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing EnterobacteriaceaeAdrian Sousa, María Teresa Pérez-Rodríguez, Adriana Soto, et al.
Revista Espanola De Enfermedades Digestivas|September 19, 2019
Training in Ultrasound for Resident Physicians in Gastroenterology: a survey and training project by the Spanish Association of Digestive Ultrasound (Asociación Española de Ecografía Digestiva - AEED)Concepcion González de Frutos, Eva Marín Serrano, Mariano Gómez-Rubio, et al.
Antiviral Therapy|January 13, 2016
Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatmentJordi Navarro, Estrella Caballero, Adrian Curran, et al.
AIDS (London, England)|February 16, 2007
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patientsManuel Crespo, Juan I Esteban, Esteban Ribera, et al.
The Journal of Antimicrobial Chemotherapy|August 18, 2010
Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patientsAdrian Curran, Mar Gutirerrez, Elisabet Deig, et al.
AIDS (London, England)|May 13, 2006
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimenEsteban Ribera, Carlos Azuaje, Rosa M Lopez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2016
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish GroupManuel Crespo, Jordi Navarro, Santiago Moreno, et al.
Journal of Psychiatric Research|March 21, 2021
First manic/hypomanic episode in obsessive-compulsive disorder patients treated with antidepressants: A systematic reviewSara Bertolín, Pino Alonso, Cinto Segalàs, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Expert Opinion on Drug Safety|December 29, 2021
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated reviewJavier De Diego-Adeliño, José Manuel Crespo, Fernando Mora, et al.
AIDS (London, England)|May 21, 2005
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapineCesar Fisac, Emilio Fumero, Manuel Crespo, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2018
Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing EnterobacteriaceaeAdrian Sousa, María Teresa Pérez-Rodríguez, Adriana Soto, et al.
Revista Espanola De Enfermedades Digestivas|September 19, 2019
Training in Ultrasound for Resident Physicians in Gastroenterology: a survey and training project by the Spanish Association of Digestive Ultrasound (Asociación Española de Ecografía Digestiva - AEED)Concepcion González de Frutos, Eva Marín Serrano, Mariano Gómez-Rubio, et al.
Antiviral Therapy|January 13, 2016
Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatmentJordi Navarro, Estrella Caballero, Adrian Curran, et al.
AIDS (London, England)|February 16, 2007
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patientsManuel Crespo, Juan I Esteban, Esteban Ribera, et al.
The Journal of Antimicrobial Chemotherapy|August 18, 2010
Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patientsAdrian Curran, Mar Gutirerrez, Elisabet Deig, et al.
AIDS (London, England)|May 13, 2006
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimenEsteban Ribera, Carlos Azuaje, Rosa M Lopez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2016
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish GroupManuel Crespo, Jordi Navarro, Santiago Moreno, et al.
Journal of Psychiatric Research|March 21, 2021
First manic/hypomanic episode in obsessive-compulsive disorder patients treated with antidepressants: A systematic reviewSara Bertolín, Pino Alonso, Cinto Segalàs, et al.
Pageof 12